Advances in Urological Cancer in 2022, from Basic Approaches to Clinical Management
Conflicts of Interest
References
- Pellerin, E.; Pellerin, F.A.; Chabaud, S.; Pouliot, F.; Bolduc, S.; Pelletier, M. Bisphenols A and S alter the bioenergetics and behaviours of normal urothelial and bladder cancer cells. Cancers 2022, 14, 4011. [Google Scholar] [CrossRef] [PubMed]
- Pellerin, E.; Caneparo, C.; Chabaud, S.; Bolduc, S.; Pelletier, M. Endocrine-disrupting effects of bisphenols on urological cancers. Environ. Res. 2021, 195, 110485. [Google Scholar] [CrossRef] [PubMed]
- Reader, K.L.; John-McHaffie, S.; Zellhuber-McMillan, S.; Jowett, T.; Mottershead, D.G.; Cunliffe, H.E.; Gold, E.J. Activin B and activin C have opposing effects on prostate cancer progression and cell growth. Cancers 2023, 15, 147. [Google Scholar] [CrossRef] [PubMed]
- Gold, E.; Risbridger, G. Activins and activin antagonists in the prostate and prostate cancer. Mol. Cell. Endocrinol. 2012, 359, 107–112. [Google Scholar] [CrossRef]
- Tossetta, G.; Fantone, S.; Gesuita, R.; Goteri, G.; Senzacqua, M.; Marcheggiani, F.; Tiano, L.; Marzioni, D.; Mazzucchelli, R. Ciliary neurotrophic factor modulates multiple downstream signaling pathways in prostate cancer inhibiting cell invasiveness. Cancers 2022, 14, 5917. [Google Scholar] [CrossRef]
- Zapala, P.; Garbas, K.; Lewandowski, Z.; Zapala, L.; Slusarczyk, A.; Slusarczyk, C.; Mielczarek, L.; Radziszewski, P. The clinical utility of systemic immune-inflammation index supporting Charlson comorbidity index and CAPRA-S Score in determining survival after radical prostatectomy. A single centre study. Cancers 2022, 14, 4135. [Google Scholar] [CrossRef]
- Shi, Z.; Zheng, J.; Liang, Q.; Liu, Y.; Yang, Y.; Wang, R.; Wang, M.; Zang, Q.; Xuan, Z.; Sun, H.; et al. Identification and validation of a novel ferroptotic prognostic genes-based signature of clear cell renal cell carcinoma. Cancers 2022, 14, 4690. [Google Scholar] [CrossRef]
- Laruelle, A.; Rocha, A.; Manini, C.; Lopez, J.I.; Inarra, E. Effects of heterogeneity on cancer: A game theory perspective. arXiv 2022, arXiv:2202.02211. [Google Scholar] [CrossRef]
- Manini, C.; Lopez-Fernandez, E.; Lawrie, C.H.; Laruelle, A.; Angulo, J.C.; Lopez, J.I. Clear cell renal cell carcinomas with aggressive behavior display low intratumor heterogeneity at the histological level. Curr. Urol. Rep. 2022, 23, 93–97. [Google Scholar] [CrossRef]
- Turajlic, S.; Xu, H.; Litchfield, K.; Rowan, A.; Horswell, S.; Chambers, T.; O’Brien, T.; López, J.I.; Watkins, T.B.K.; Nicol, D.; et al. Deterministic evolutionary trajectories influence primary tumor growth. Cell 2018, 173, 595–610. [Google Scholar] [CrossRef] [Green Version]
- Fu, X.; Zhao, Y.; Lopez, J.I.; Rowan, A.; Au, L.; Fendler, A.; Hazell, S.; Xu, H.; Horswell, S.; Shepherd, S.; et al. Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nat. Ecol. Evol. 2022, 6, 88–102. [Google Scholar] [CrossRef] [PubMed]
- Lopez, J.I.; Cortés, J.M. Multi-site tumor sampling (MSTS): A new tumor selection method to enhance intratumor heterogeneity detection. Hum. Pathol. 2017, 64, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Manini, C.; Lopez-Fernandez, E.; Lopez, J.I. Towards personalized sampling in clear cell renal cell carcinomas. Cancers 2022, 14, 3381. [Google Scholar] [CrossRef] [PubMed]
- Christenson, M.; Song, C.S.; Liu, Y.G.; Chatterjee, B. Precision targets for intercepting the lethal progression of prostate cancer: Potential avenues for personalized therapy. Cancers 2022, 14, 892. [Google Scholar] [CrossRef] [PubMed]
- Wollersheim, B.M.; van Asselt, K.M.; Pos, F.J.; Akdemir, E.; Crouse, S.; van der Poel, H.G.; Aaronson, N.K.; van de Poll-Franse, L.V.; Boekhout, A.H. Specialist versus primary care prostate cancer follow-up: A process evaluation of a randomized controlled trial. Cancers 2022, 14, 3166. [Google Scholar] [CrossRef]
- Wollersheim, B.M.; van der Poel, H.G.; van Asselt, K.M.; Pos, F.J.; Tillier, C.N.; Akdemir, E.; Vis, A.N.; Lampe, M.I.; van den Bergh, R.; Somford, D.M.; et al. Quality of early prostate cancer follow-up care from the patients’ perspective. Support Care Cancer 2022, 30, 10077–10087. [Google Scholar] [CrossRef]
- Lumbreras, B.; Parker, L.A.; Caballero-Romeu, J.P.; Gómez-Pérez, L.; Puig-García, M.; López-Garrigós, M.; García, N.; Hernández-Aguado, I. Variables associated with false-positive PSA results: A cohort study with real-world data. Cancers 2022, 14, 261. [Google Scholar] [CrossRef]
- Kilpeläinen, T.P.; Tammela, T.L.; Roobol, M.; Hugosson, J.; Ciatto, S.; Nelen, V.; Moss, S.; Määttänen, L.; Auvinen, A. False-positive screening results in the European randomized study of screening for prostate cancer. Eur. J. Cancer 2011, 47, 2698–2705. [Google Scholar] [CrossRef]
- Zhao, Y.; Simpson, B.S.; Morka, N.; Freeman, A.; Kirkman, A.; Kelly, D.; Whitaker, H.C.; Emberton, M.; Norris, J.M. Comparison of multiparametric magnetic resonance imaging with prostate-specific membrane antigen positron-emission tomography imaging in primary prostate cancer diagnosis: A systematic review and meta-analysis. Cancers 2022, 14, 3497. [Google Scholar] [CrossRef]
- Stavrinides, V.; Syer, T.; Hu, Y.; Giganti, F.; Freeman, A.; Karapanagiotis, S.; Bott, S.R.J.; Brown, L.C.; Burns-Cox, N.; Dudderidge, T.J.; et al. False positive multiparametric magnetic resonance imaging phenotypes in the biopsy-naïve prostate: Are they distinct from significant cancer-associated lesions? Lessons from PROMIS. Eur. Urol. 2021, 79, 20–29. [Google Scholar] [CrossRef]
- Wong, L.-M.; Koschel, S.; Whish-Wilson, T.; Farag, M.; Bolton, D.; Zargar, H.; Corcoran, N.; Lawrentschuk, N.; Christov, A.; Thomas, L. Investigating PSMA-PET/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance. World J. Urol. 2023, 41, 463–469. [Google Scholar] [CrossRef] [PubMed]
- Woo, H.H.; Khanani, H.; Thompson, N.J.; Sorensen, B.J.; Baskaranathan, S.; Bergersen, P.; Chalasani, V.; Dean, T.; Dias, M.; Symons, J.; et al. Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study). Eur. Urol. Open Sci. 2022, 47, 119–125. [Google Scholar] [CrossRef] [PubMed]
- Lopci, E.; Lazzeri, M.; Colombo, P.; Casale, P.; Buffi, N.M.; Saita, A.; Peschechera, R.; Hurle, R.; Marzo, K.; Leonardi, L.; et al. Diagnostic performance and clinical impact of PSMA PET/CT versus mpMRI in patients with a high suspicion of prostate cancer and previously negative biopsy: A prospective trial (PROSPET-BX). Urol. Int. 2023. [Google Scholar] [CrossRef]
- Rasul, S.; Haug, A.R. Clinical applications of PSMA PET examination in patients with prostate cancer. Cancers 2022, 14, 3768. [Google Scholar] [CrossRef]
- Mehrens, D.; Kramer, K.K.M.; Unterrainer, L.M.; Beyer, L.; Bartenstein, P.; Froelich, M.F.; Tollens, F.; Ricke, J.; Rübenthaler, J.; Schmidt-Hegemann, N.-S.; et al. Cost-effectiveness analysis of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer. J. Natl. Compr. Cancer Netw. 2023, 21, 43–50.e2. [Google Scholar] [CrossRef]
- Petit, C.; Delouya, G.; Taussky, D.; Barkati, M.; Lambert, C.; Beauchemin, M.-C.; Clavel, S.; Mok, G.; Gauthier Paré, A.-S.; Nguyen, T.-V.; et al. PSMA-PET/CT guided intensification of radiotherapy for prostate cancer (PSMAgRT): Findings of detection rate, impact on cancer management, and early toxicity from a phase 2 randomised controlled trial. Int. J. Radiat. Oncol. Biol. Phys. 2023. [Google Scholar] [CrossRef]
- Hiroshima, Y.; Ishikawa, H.; Iwai, Y.; Wakatsuki, M.; Utsumi, T.; Suzuki, H.; Akakura, K.; Harada, M.; Sakurai, H.; Ichikawa, T.; et al. Safety and efficacy of carbon-ion radiotherapy for elderly patients with high-risk prostate cancer. Cancers 2022, 14, 4015. [Google Scholar] [CrossRef]
- Ishikawa, H.; Hiroshima, Y.; Kanematsu, N.; Inaniwa, T.; Shirai, T.; Imai, R.; Suzuki, H.; Akakura, K.; Wakatsuki, M.; Ichikawa, T.; et al. Carbon-ion radiotherapy for urological cancers. Int. J. Urol. 2022, 29, 1109–1119. [Google Scholar] [CrossRef]
- Malouff, T.D.; Mahajan, A.; Krishnan, S.; Beltran, C.; Seneviratne, D.S.; Trifiletti, D.M. Carbon ion therapy: A modern review of an emerging technology. Front. Oncol. 2020, 10, 82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gómez-Aparicio, M.A.; Valero, J.; Caballero, B.; García, R.; Hernando-Requejo, O.; Montero, Á.; Gómez-Iturriaga, A.; Zilli, T.; Ost, P.; López-Campos, F.; et al. Extreme hypofractionation with SBRT in localized prostate cancer. Curr. Oncol. 2021, 28, 2933–2949. [Google Scholar] [CrossRef] [PubMed]
- Corkum, M.T.; Achard, V.; Morton, G.; Zilli, T. Ultrahypofractionated radiotherapy for localised prostate cancer: How far can we go? Clin. Oncol. (R. Coll. Radiol.) 2022, 34, 340–349. [Google Scholar] [CrossRef] [PubMed]
- D’Altilia, N.; Mancini, V.; Falagario, U.G.; Martino, L.; Di Nauta, M.; Calò, B.; Del Giudice, F.; Basran, S.; Chung, B.I.; Porreca, A.; et al. A matched-pair analysis after robotic and retropubic radical prostatectomy: A new definition of continence and the impact of different surgical techniques. Cancers 2022, 14, 4350. [Google Scholar] [CrossRef] [PubMed]
- Abrams, P.; Constable, L.D.; Cooper, D.; MacLennan, G.; Drake, M.J.; Harding, C.; Mundy, A.; McCormack, K.; McDonald, A.; Norrie, J.; et al. Outcomes of a noninferiority randomised controlled trial of surgery for men with urodynamic stress incontinence after prostate surgery (MASTER). Eur. Urol. 2021, 79, 812–823. [Google Scholar] [CrossRef] [PubMed]
- Angulo, J.C.; Arance, I.; Esquinas, C.; Dorado, J.F.; Marcelino, J.P.; Martins, F.E. Outcome measures of adjustable transobturator male system with pre-attached scrotal port for male stress urinary incontinence after radical prostatectomy: A prospective study. Adv. Ther. 2017, 34, 1173–1183. [Google Scholar] [CrossRef]
- Angulo, J.C.; Cruz, F.; Esquinas, C.; Arance, I.; Manso, M.; Rodríguez, A.; Pereira, J.; Ojea, A.; Carballo, M.; Rabassa, M.; et al. Treatment of male stress urinary incontinence with the adjustable transobturator male system: Outcomes of a multi-center Iberian study. Neurourol. Urodyn. 2018, 37, 1458–1466. [Google Scholar] [CrossRef]
- Esquinas, C.; Angulo, J.C. Effectiveness of adjustable transobturator male system (ATOMS) to treat male stress incontinence: A systematic review and meta-analysis. Adv. Ther. 2019, 36, 426–441. [Google Scholar] [CrossRef] [Green Version]
- Yang, Y.K.; Hsieh, M.L.; Chen, S.Y.; Liu, C.Y.; Lin, P.H.; Kan, H.C.; Pang, S.T.; Yu, K.J. Clinical benefits of indocyanine green fluorescence in robot-assisted partial nephrectomy. Cancers 2022, 14, 3032. [Google Scholar] [CrossRef]
- Angulo, J.C.; Shapiro, O. The changing therapeutic landscape of metastatic renal cancer. Cancers 2019, 11, 1227. [Google Scholar] [CrossRef] [Green Version]
- Doehn, C.; Bögemann, M.; Grünwald, V.; Welslau, M.; Bedke, J.; Schostak, M.; Wolf, T.; Ehneß, R.; Degenkolbe, E.; Witecy, S.; et al. The non-interventional PAZOREAL Study to assess the effectiveness and safety of pazopanib in a real-life setting: Reflecting a changing mRCC treatment landscape. Cancers 2022, 14, 5486. [Google Scholar] [CrossRef]
- Nunes-Xavier, C.E.; Angulo, J.C.; Pulido, R.; López, J.I. A critical insight into the clinical translation of PD-1/PD-L1 blockade therapy in clear cell renal cell carcinoma. Curr. Urol. Rep. 2019, 20, 1. [Google Scholar] [CrossRef]
- Plata, A.; Guerrero-Ramos, F.; Garcia, C.; González-Díaz, A.; Gonzalez-Valcárcel, I.; De la Morena, J.M.; Díaz-Goizueta, F.J.; Del Álamo, J.F.; Gonzalo, V.; Montero, J.; et al. Long-term experience with hyperthermic chemotherapy (HIVEC) using Mitomycin-C in patients with non-muscle invasive bladder cancer in Spain. J. Clin. Med. 2021, 10, 5105. [Google Scholar] [CrossRef] [PubMed]
- Guerrero-Ramos, F.; González-Padilla, D.A.; González-Díaz, A.; de la Rosa-Kehrmann, F.; Rodríguez-Antolín, A.; Inman, B.A.; Villacampa-Aubá, F. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: Results of the HIVEC-HR randomized clinical trial. World J. Urol. 2022, 40, 999–1004. [Google Scholar] [CrossRef] [PubMed]
- Angulo, J.C.; Álvarez-Ossorio, J.L.; Domínguez-Escrig, J.L.; Moyano, J.L.; Sousa, A.; Fernández, J.M.; Gómez-Veiga, F.; Unda, M.; Carballido, J.; Carrero, V.; et al. Hyperthermic Mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: Results of the HIVEC-1 trial. Eur. Urol. Oncol. 2023, 6, 58–66. [Google Scholar] [CrossRef] [PubMed]
- Angulo, J.C.; Lopez, J.I.; Flores, N.; Toledo, J.D. The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification. J. Cancer Res. Clin. Oncol. 1993, 119, 578–593. [Google Scholar] [CrossRef] [PubMed]
- Calvete, J.; Larrinaga, G.; Errarte, P.; Martín, A.M.; Dotor, A.; Esquinas, C.; Nunes-Xavier, C.E.; Pulido, R.; López, J.I.; Angulo, J.C. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Hum. Pathol. 2019, 91, 61–68. [Google Scholar] [CrossRef] [PubMed]
- Bian, Z.; Chen, J.; Liu, C.; Ge, Q.; Zhang, M.; Meng, J.; Liang, C. Landscape of the intratumoral microenvironment in bladder cancer: Implications for prognosis and immunotherapy. Comput. Struct. Biotechnol. J. 2022, 21, 74–85. [Google Scholar] [CrossRef]
- Konala, V.M.; Adapa, S.; Aronow, W.S. Immunotherapy in bladder cancer. Am. J. Ther. 2022, 29, e334–e337. [Google Scholar] [CrossRef]
- Rizzo, A.; Mollica, V.; Santoni, M.; Palmiotti, G.; Massari, F. Pathologic complete response in urothelial carcinoma patients receiving neoadjuvant immune checkpoint inhibitors: A Meta-Analysis. J. Clin. Med. 2022, 11, 1038. [Google Scholar] [CrossRef]
- Ha, J.S.; Jeon, J.; Ko, J.C.; Lee, H.S.; Yang, Y.; Kim, D.; Kim, J.S.; Ham, W.S.; Choi, Y.D.; Cho, K.S. Intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial carcinoma is associated with flexible diagnostic ureteroscopy, but not with rigid diagnostic ureteroscopy. Cancers 2022, 14, 5629. [Google Scholar] [CrossRef]
- Marchioni, M.; Primiceri, G.; Cindolo, L.; Hampton, L.J.; Grob, M.B.; Guruli, G.; Schips, L.; Shariat, S.F.; Autorino, R. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: A systematic review and meta-analysis. BJU Int. 2017, 120, 313–319. [Google Scholar] [CrossRef] [Green Version]
- Guo, R.Q.; Hong, P.; Xiong, G.Y.; Zhang, L.; Fang, D.; Li, X.S.; Zhang, K.; Zhou, L.Q. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: A meta-analysis. BJU Int. 2018, 121, 184–193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nowak, Ł.; Krajewski, W.; Chorbińska, J.; Kiełb, P.; Sut, M.; Moschini, M.; Teoh, J.Y.-C.; Mori, K.; Del Giudice, F.; Laukhtina, E.; et al. The impact of diagnostic ureteroscopy prior to radical nephroureterectomy on oncological outcomes in patients with upper tract urothelial carcinoma: A comprehensive systematic review and meta-analysis. J. Clin. Med. 2021, 10, 4197. [Google Scholar] [CrossRef] [PubMed]
- Rouprêt, M.; Babjuk, M.; Burger, M.; Capoun, O.; Cohen, D.; Compérat, E.M.; Cowan, N.C.; Dominguez-Escrig, J.L.; Gontero, P.; Mostafid, A.H.; et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur. Urol. 2021, 79, 62–79. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Manini, C.; López-Fernández, E.; López, J.I.; Angulo, J.C. Advances in Urological Cancer in 2022, from Basic Approaches to Clinical Management. Cancers 2023, 15, 1422. https://doi.org/10.3390/cancers15051422
Manini C, López-Fernández E, López JI, Angulo JC. Advances in Urological Cancer in 2022, from Basic Approaches to Clinical Management. Cancers. 2023; 15(5):1422. https://doi.org/10.3390/cancers15051422
Chicago/Turabian StyleManini, Claudia, Estíbaliz López-Fernández, José I. López, and Javier C. Angulo. 2023. "Advances in Urological Cancer in 2022, from Basic Approaches to Clinical Management" Cancers 15, no. 5: 1422. https://doi.org/10.3390/cancers15051422